165 related articles for article (PubMed ID: 36120910)
1. Longitudinal assessment of quality of life in indolent non-Hodgkin lymphomas managed with active surveillance.
Major A; Wright R; Hlubocky FJ; Smith SM; Prochaska MT
Leuk Lymphoma; 2022 Dec; 63(14):3331-3339. PubMed ID: 36120910
[TBL] [Abstract][Full Text] [Related]
2. Worsening Quality of Life in Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients in Active Surveillance: A 12-Month Longitudinal Study.
Trevino KM; Martin P; Chen Z; Leonard JP
Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):82-88. PubMed ID: 34479847
[TBL] [Abstract][Full Text] [Related]
3. Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now.
Galia M; Albano D; Tarella C; Patti C; Sconfienza LM; Mulè A; Alongi P; Midiri M; Lagalla R
Eur Radiol; 2018 Mar; 28(3):1187-1193. PubMed ID: 29018927
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
Cheson BD; Trask PC; Gribben JG; Dimier N; Kimby E; Lugtenburg PJ; Thieblemont C; Wassner-Fritsch E; Launonen A; Sehn LH
Ann Hematol; 2017 Feb; 96(2):253-259. PubMed ID: 27900446
[TBL] [Abstract][Full Text] [Related]
5. Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study.
Kang D; Cho J; Kim IR; Kim MK; Kim WS; Kim SJ
Cancer Res Treat; 2018 Oct; 50(4):1051-1063. PubMed ID: 29121713
[TBL] [Abstract][Full Text] [Related]
6. Quality of life appears similar between survivors of indolent and aggressive non-Hodgkin lymphoma.
Blaes AH; Ma L; Zhang Y; Peterson BA
Leuk Lymphoma; 2011 Nov; 52(11):2105-10. PubMed ID: 21740095
[TBL] [Abstract][Full Text] [Related]
7. International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20).
Oerlemans S; Efficace F; Kyriakou C; Freitas AC; Shamieh O; Creutzberg CL; Lehmann J; Petranovic D; Nagele E; Bredart A; Dong D; Scholz CW; Caocci G; Molica S; Griskevicius L; Xochelli A; Kieffer JM; Agelink van Rentergem JA; Alrjoub W; Mueller A; Gomes Da Silva M; Alves da Costa F; Malak S; Cocks K; van de Poll-Franse LV;
Cancer; 2023 Sep; 129(17):2727-2740. PubMed ID: 37204189
[TBL] [Abstract][Full Text] [Related]
8. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
9. Persistent symptoms of fatigue, neuropathy and role-functioning impairment among indolent non-Hodgkin lymphoma survivors: A longitudinal PROFILES registry study.
Ekels A; van de Poll-Franse LV; Posthuma EFM; Kieffer J; Issa DE; Koster A; Nijziel MR; Pruijt JHFM; Stevens WBC; Tick LW; Oerlemans S
Br J Haematol; 2022 Jun; 197(5):590-601. PubMed ID: 35365860
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW - Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting).
Ansmann L; Winter N; Ernstmann N; Heidenreich A; Weissbach L; Herden J
BJU Int; 2018 Sep; 122(3):401-410. PubMed ID: 29603553
[TBL] [Abstract][Full Text] [Related]
11. Quality of Life is Similar between Long-term Survivors of Indolent and Aggressive Non-Hodgkin Lymphoma.
Beaven AW; Samsa G; Zimmerman S; Smith SK
Cancer Invest; 2016 Jul; 34(6):279-85. PubMed ID: 27379565
[TBL] [Abstract][Full Text] [Related]
12. Systematic literature review of health-related quality of life among aggressive non-Hodgkin lymphoma survivors.
Lin VW; Blaylock B; Epstein J; Purdum A
Curr Med Res Opin; 2018 Aug; 34(8):1529-1535. PubMed ID: 29741105
[TBL] [Abstract][Full Text] [Related]
13. Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission.
Truong Q; Shah N; Knestrick M; Curley B; Hu Y; Craig M; Hamadani M
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):50-5. PubMed ID: 24119465
[TBL] [Abstract][Full Text] [Related]
14. Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study.
Busson R; van der Kaaij M; Mounier N; Aleman BMP; Thiéblemont C; Stamatoullas A; Ribrag V; Tilly H; Haioun C; Casasnovas RO; Kluin-Nelemans HC; Henry-Amar M
Health Qual Life Outcomes; 2019 Jul; 17(1):115. PubMed ID: 31266501
[TBL] [Abstract][Full Text] [Related]
15. Unmet needs of non-Hodgkin lymphoma survivors in Korea: prevalence, correlates, and associations with health-related quality of life.
Kim SH; Lee S; Kim SH; Ok ON; Kim IR; Choi E; Kang YK; Kim SJ; Lee MH
Psychooncology; 2017 Mar; 26(3):330-336. PubMed ID: 27073128
[TBL] [Abstract][Full Text] [Related]
16. Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas.
Saleh K; Michot JM; Schernberg A; Lazarovici J; Chahine C; Danu A; Khalife-Saleh N; Rossignol J; Ghez D; Martin V; Mazeron R; Fermé C; Boros A; Ribrag V; Girinsky T
Cancer Med; 2020 Jun; 9(11):3725-3732. PubMed ID: 32249547
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/computed tomography may predict the outcome of newly diagnosed indolent non-Hodgkin lymphoma in patients managed with initial 'watch-and-wait' approach.
Luo Y; Zhang Y; Pan Q; Zhang Y; Li F
Nucl Med Commun; 2020 Dec; 41(12):1283-1290. PubMed ID: 32925828
[TBL] [Abstract][Full Text] [Related]
18. Quality of life and related demographic factors in long-term survivors of childhood non-Hodgkin's lymphoma.
Hu Y; Wu LH; Guan HJ; Wu SY; Liu LZ; Cai RQ; Xu YJ; Zhang YZ; Sun XF; Zhu J
Zhongguo Dang Dai Er Ke Za Zhi; 2021 Sept 15; 23(9):882-888. PubMed ID: 34535201
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection.
Levine AM; Sadeghi S; Espina B; Tulpule A; Nathwani B
Cancer; 2002 Mar; 94(5):1500-6. PubMed ID: 11920507
[TBL] [Abstract][Full Text] [Related]
20. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
